Imidazopyridines Syk inhibitors
Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
1. At least one chemical entity chosen from compounds of Formula I:
and pharmaceutically acceptable salts thereof, wherein
R 1 is optionally substituted phenyl;
R 2 is chosen from 2,3-dimethyl-2H-indazol-6-yl, 1H-indazolyl-6-yl, 1-methyl-1H-indazol-5-yl, 1-methyl-1H-indazol-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl, 1-(2-hydroxyethyl)-1H-benzo[d]imidazol-2(3H)-one-5-yl, 3-amino-1H-indazol-6-yl, 1H-pyrrolo[3,2-b]pyridine-6-yl, 1,3-benzoxazol-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-6-yl, 2-hydroxyquinoxalin-7-yl, 3-aminoquinolin-6-yl, 2,3-dihydro-1H-indol-6-yl, 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one, (3-hydroxyethyl)-1H-indol-6-yl, benzothiazolyl, 2-aminoquinazolin-6-yl, 3,3-dimethylindolin-2-one, 2,3-dihydro-1H-indol-2-one, 4-fluoro-1H-indazol-6-yl, 5-fluoro-1H-indazol-6-yl, and 3-amino-1H-indazol-6-yl; and
R 3 is chosen from hydrogen, lower alkyl, halogen, carboxamido or CO 2 H.
2. At least one chemical entity of claim 1 , wherein R 1 is phenyl optionally substituted with one or more groups chosen from
hydroxy;
—NR b R c wherein R b is chosen from hydrogen and C 1 -C 6 alkyl optionally substituted with one or two groups chosen from hydroxy and —OC 1 -C 4 alkyl and R c is independently chosen from hydrogen and C 1 -C 4 alkyl optionally substituted with one or two groups chosen from hydroxy and —OC 1 -C 4 alkyl;
heterocycloalkyl optionally substituted with one or two groups chosen from hydroxy, C 3 -C 6 cycloalkyl, C 1 -C 4 alkyl, —C 1 -C 4 alkyl-OH, —C 1 -C 4 alkyl-O—C 1 -C 4 alkyl, —C 1 -C 4 alkyl-NH 2 , —N(C 1 -C 4 alkyl)(C 1 -C 4 alkyl), —NH(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl-OH), and —OC 1 -C 4 alkyl;
—OC 1 -C 6 alkyl optionally substituted with one or two groups chosen from hydroxy, C 3 -C 6 cycloalkyl, C 1 -C 4 alkyl, —C 1 -C 4 alkyl-OH, —C 1 -C 4 alkyl-O—C 1 -C 4 alkyl, —C 1 -C 4 alkyl-NH 2 , —N(C 1 -C 4 alkyl)(C 1 -C 4 alkyl), —NH(C 1 -C 4 alkyl), and —OC 1 -C 4 alkyl; and
C 1 -C 6 alkyl optionally substituted with one or two groups chosen from hydroxy, C 3 -C 6 cycloalkyl, C 1 -C 4 alkyl, —C 1 -C 4 alkyl-OH, —C 1 -C 4 alkyl-O—C 1 -C 4 alkyl, —C 1 -C 4 alkyl-NH 2 , —N(C 1 -C 4 alkyl)(C 1 -C 4 alkyl), —NH(C 1 -C 4 alkyl), and —OC 1 -C 4 alkyl.
3. At least one chemical entity chosen from compounds of Formula I:
and pharmaceutically acceptable salts thereof, wherein
R 1 is optionally substituted phenyl;
R 2 is chosen from 1H-indazolyl-6-yl, 1-methyl-1H-indazol-5-yl, 1-methyl-1H-indazol-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl, 1,3-benzoxazol-6-yl, 3-aminoquinolin-6-yl, 1H-pyrrolo[3,2-b]pyridin-6-yl, and 2,3-dihydro-1H-indol-2-one-6-yl; and
R 3 is chosen from hydrogen, lower alkyl, halogen, carboxamido or CO 2 H.
4. At least one chemical entity chosen from compounds of Formula I:
and pharmaceutically acceptable salts thereof, wherein
R 1 is optionally substituted phenyl;
R 2 is chosen from 2,3-dimethyl-2H-indazol-6-yl, 1H-indazolyl-6-yl, 1-methyl-1H-indazol-5-yl, 1-methyl-1H-indazol-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl, 1-(2-hydroxyethyl)-1H-benzo[d]imidazol-2(3H)-one-5-yl, 3-amino-1H-indazol-6-yl, 1H-pyrrolo[3,2-b]pyridine-6-yl, 1,3-benzoxazol-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-6-yl, 2-hydroxyquinoxalin-7-yl, 3-aminoquinolin-6-yl, 2,3-dihydro-1H-indol-6-yl, 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one, (3-hydroxyethyl)-1H-indol-6-yl, benzothiazolyl, 2-aminoquinazolin-6-yl, 3,3-dimethylindolin-2-one, 2,3-dihydro-1H-indol-2-one, 4-fluoro-1H-indazol-6-yl, 5-fluoro-1H-indazol-6-yl, and 3-amino-1H-indazol-6-yl; and
R 3 is chosen from hydrogen and methyl.
5. At least one chemical entity chosen from compounds of Formula I:
and pharmaceutically acceptable salts thereof, wherein
R 1 is optionally substituted phenyl;
R 2 is chosen from 2,3-dimethyl-2H-indazol-6-yl, 1H-indazolyl-6-yl, 1-methyl-1H-indazol-5-yl, 1-methyl-1H-indazol-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-3-one-6-yl, 1-(2-hydroxyethyl)-1H-benzo[d]imidazol-2(3H)-one-5-yl, 3-amino-1H-indazol-6-yl, 1H-pyrrolo[3,2-b]pyridine-6-yl, 1,3-benzoxazol-6-yl, 3,4-dihydro-2H-1,4-benzoxazin-6-yl, 2-hydroxyquinoxalin-7-yl, 3-aminoquinolin-6-yl, 2,3-dihydro-1H-indol-6-yl, 1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one, (3-hydroxyethyl)-1H-indol-6-yl, benzothiazolyl, 2-aminoquinazolin-6-yl, 3,3-dimethylindolin-2-one, 2,3-dihydro-1H-indol-2-one, 4-fluoro-1H-indazol-6-yl, 5-fluoro-1H-indazol-6-yl, and 3-amino-1H-indazol-6-yl; and
R 3 is hydrogen.
6. N-(3,4-dimethoxyphenyl)-6-(1H-indazol-6-yl)imidazo[1,2-a]pyridin-8-amine, or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising at least one chemical entity of claim 1 , together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients.